Miltenyi Biomedicine GmbH

Quick facts

Phase 2 pipeline

• MB-CART19.1
• MB-CART2019.1

Phase 1 pipeline

• anti-CD19 CAR T cell therapy
• MB-CART20.1
• MB-CART2019.1 Dose level 1
• MB-CART2019.1 Dose level 2
• MB-dNPM1-TCR.1
• zamtocabtagene autoleucel

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Miltenyi Biomedicine GmbH portfolio CI brief
• Miltenyi Biomedicine GmbH pipeline updates RSS

Related

• Sector hub: All tracked pharma companies